comparemela.com

Latest Breaking News On - Ping an shionogi - Page 1 : comparemela.com

Execution of Sub-license Agreement from Ping An-Shionogi Hong Kong to Ildong for Ensitrelvir Fumaric Acid (S-217622), a Therapeutic Drug for COVID-19, for South Korea

Execution of Sub-license Agreement from Ping An-Shionogi Hong Kong to Ildong for Ensitrelvir Fumaric Acid (S-217622), a Therapeutic Drug for COVID-19, for South Korea
shionogi.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from shionogi.com Daily Mail and Mail on Sunday newspapers.

Ping An-Shionogi Joint Venture Launched in Shanghai, Expanding Footprint in Healthcare Industry

Share this article Share this article HONG KONG and SHANGHAI, July 29, 2021 /PRNewswire/ Ping An Insurance (Group) Company of China, Ltd. (hereafter Ping An or the Group , HKEX: 2318; SSE: 601318) announced that Ping An-Shionogi Co., Ltd. (Ping An-Shionogi), a joint venture between Ping An and Shionogi & Co., Ltd., has been launched in Shanghai. Launch ceremony of Ping An-Shionogi in Shanghai Ping An-Shionogi is a Healthcare as a Service (HaaS) enterprise, an integrated medical and healthcare platform, for public health and patients. The joint venture is a collaboration between the Ping An and Shionogi in drug research, development, production and sales. It is based on Ping An s sophisticated healthcare ecosystem and advanced digital technology and Shionogi s strengths in drug research and development. Using Ping An s leading healthtech capabilities, resources and advantages in insurance and financial services, and Shionogi s drug development capability and experience in t

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.